Summary
Biotechnology derived medicines will have an increasing impact not only upon medical practice but also upon the working lives of many pharmaceutical scientists. Whilst such medicines may be viewed as highly sophisticated to the clinician and scientist, the consumer will still rightly demand that they are both efficacious and safe. Impacting as it does upon all phases of drug development and facilitating quantitative relationship between administered dose and systemic drug concentration, pharmacokinetics has an important role to play in the development ofall medicines. Bioanalysis is an essential prelude to any pharmacokinetic investigation. For many biotechnology products the immunoassay and bioassay methodologies employed are often relatively non-specific and imprecise and yield assay dependent pharmacokinetic parameters. Other factors may also confound the pharmacokinetic evaluation of biotechnological products. In vivo binding proteins (including antibodies) may not only interfere with bioanalytical methodology but also have a significant effect on the pharmacokinetics and biological activity of certain macromolecules. Antibody formation is a particular problem in the preclinical evaluation of human proteins. Unlike most conventional pharmaceuticals, the rate and time of delivery into the systemic circulation is a fundamental component of the biological activity of many biological molecules.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Biotech ’96. Pursuing Sustainability. (1995): Palo Alto, Ernst and Young LCP.
Dollery C.T. (1973): Pharmacokinetics — master or servant? Eur. J. Clin. Pharmacol., 6, 1–2.
Riegelman S., Rowland M., Benet L.Z. (1973): Use of isotopes in bioavailability testing. J. Pharmacokinet. Biopharm., 1, 83–87.
Ariëns E.J. (1984): Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol., 26, 663–668.
Bailey G.S. (1984): Radioiodination of proteins. Methods Mol. Biol., 1, 325.
Parker C.W. (1990): Radiolabelling of proteins. Methods Enzymol., 182, 721–737.
Woltanski K-P., Besch W., Keilacker H., Ziegler, M., Kohnert K-D. (1990): Radioiodination of peptide hormone and immunoglobulin preparations: comparison of the chloramine T and iodogen method. Exp. Clin. Endocrinol., 95, 39–46.
Cossum P.A., Dwyer K.A., Roth M., et al. (1992): The disposition of a human relaxin (hRIx-2) in pregnant and non-pregnant rats. Pharm. Res., 9, 415–420.
Bennett H.P.J., McMartin C. (1979): Peptide hormones and their analogues: distribution, clearance, from the circulation and inactivation in vivo. Pharmacol. Rev., 30, 247–292.
Cameron D.P., Burger H.G., Catt K.J., Dong A. (1969): Metabolic clearance rate of radioiodinated human growth hormone in man. J. Clin. Invest., 48, 1600–1608.
Parker M.L., Utinger R.D., Daughaday W.H.. (1962): Studies on human growth hormone. II. The physiological disposition and metabolic fate of human growth hormone in man. J. Clin. Invest., 41, 262–268.
Regoeczi E. (1987): Iodine-labelled plasma proteins. Boca Raton, CRC, pp.6, 112, 116–117.
Schwenk W.F., Tsalikain E., Beaufrere B., Haymond M.W. (1985): Recycling of an amino acid label with prolonged isotope infusion: implications for kinetic studies. Am. J. Physiol., 248, E482-E487.
Bloom H.G., Crocket D.J., Stewart F.S. (1958): The effects of radiation on the stability of radioiodinated human serum albumin. Br. J. Radiol., 31, 377–384.
Van der Abbeele A.D., Aronson R.A., Adelstein S.J., Kassis A.I. (1988): Does the in vitro immunoreactivity of an antibody reflect its in vivo behaviour? J. Nucl. Med. Allied Sci., 32, 260–267.
Chan D.W., Perlstein M.T. (1987): Immunoassay — A Practical Guide. New York, Academic Press.
Kemeny D.M., Challacombe S.J. (eds) (1988): ELISA and other Solid Phase Immunoassays. New York, Wiley.
Gosling J.P. (1990): A decade of development of immunoassay methodology. Clin. Chem., 36, 1408–1427.
Chen A.B., Baker D.L., Ferraiolo B.L.. (1991): Points to consider in correlating bioassays and immunoassays in the quantitation of peptides and proteins In: Garzone P.D., Colburn W.A., Mokotoff W.A. (Eds) Peptides, Peptoids and Proteins. Cincinnati, Harvey Whitney Books, pp. 53–71.
La Bella F.S., Geiger J.D., Glavin G.B. (1985): Administered peptides inhibit the degradation of endogenous peptides: the dilemma of distinguishing direct from indirect effects. Peptides, 6, 645–660.
Pringle P.J., Hindmarsh P.C., De Silvio L., Teale J.D., Kurtz A.B., Brook C.G.D. (1989): The measurement and effect of growth hormone in the presence of growth hormone-binding antibodies. J. Endocrinol., 121, 193–199.
Lucas C., Bald L.N., Martin M.C., et al. (1989): An enzyme linked immunosorbent assay to study human relaxin in human pregnancy and in pregnant rhesus monkeys. J. Endocrinol., 120, 449–457.
Porchet H.C., Le Cotonnec J-Y., Loumaye E. (1994): Clinical pharmacology of recombinant human follicle-stimulating hormone. III. Pharmacokinetic-pharmacodynamic modelling after repeated subcutaneous administration. Fertil. Steril., 61, 687–695.
Le Cotonnec J-Y., Porchet H.C., Beltrami V., Khan A.Z., Toon S., Rowland M. (1994): Clinical pharmacology of recombinant human follicle stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil. Steril., 61, 669–678.
Khan A.Z., Davis J.D., Toon, S., et al. (1994): A study investigating the pharmacokinetic and pharmacodynamic equivalence of two r-hGH formulations administered subcutaneously. Br. J. Clin. Pharmacol., 38, 177P.
Toon S. (1995): Problems of assessment of bioavailability/bioequivalence of administered endogenous substances. In: Blume H.H., Midha K.K., (Eds) Bio-International 2. Bioavailability, Bioequivalence and Pharmacokinetic Studies. Stuttgart, Medpharm, pp. 161–170.
Mordenti J., Chappell W. (1989): The use of interspecies scaling in toxicokinetics. In: Yacobi A., Skelly J.P., Batra V.K. (Eds) Toxicokinetics and New Drug Development. New York, Pergamon, pp. 42–96.
Mordenti J., Green J.D. (1991): The role of pharmacokinetics and pharmacodynamics in the development of therapeutic proteins. In: Rescigno A., Thakur A.K., (Eds.) New Trends in Pharmacokinetics. New York, Plenum, pp. 411–424.
Mordenti J., Chen S., Moore J., Ferraiolo B. (1990): Total body clearance of recombinant and synthetic proteins are well described by an allometric relationship. Toxicologist, 10, 239.
Mordenti J., Shaieb D., Chow P., et al. (1991): Pre-clinical safety evaluation strategy for biomacromolecules — a perspective. In: Gad S.C. (Ee.d) Safety Assessment for Pharmaceuticals. New York, Van Nostrand Reinhold.
Working P.K. (1992): Potential effects of antibody induction by protein drugs. In: Ferraiolo B.L., Mohler M.A., Gloff C.A. (Eds). Protein Pharmacokinetics and Metabolism. New York, Plenum Press, pp. 73–92.
Vallbracht A., Trainer J., Flehmig B., Joester K.E., Niethammer D. (1981): Interferon neutralising antibodies in a patient treated with human fibroblast interferon. Nature, 289, 496–497.
Trown P.W., Kramer M.J., Dennin R.A., et al. (1983): Antibodies to human leukocyte interferon in cancer patients. Lancet, 1, 81–84.
Spiegel R.J., Spicehandler J.R., Jacobs S.L., Oden E.M. (1986): Low incidence of neutralising factors in patients receiving recombinant-alpha-2b interferon (Intron-A) Am. J. Med., 80, 223–228.
Hawkins M., Horning S., Konrand M., et al. (1985): Phase I evaluation of a synthetic mutant of β-interferon. Cancer Res., 45, 5914–5920.
Kaplan S.L., August G.P., Blethen S.L., et al. (1986): Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet, 1, 697–700.
Fineberg S., Galloway J., Fineberg N., Rathburn M., Hufferd S. (1983): Immunogenicity of recombinant DNA human insulin. Diabetologia, 25, 465–469.
Nilsson I.M., Berntorp E., Zettervall O., Dahlback B. (1990): Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in haemophilia A patients. Blood, 75, 378–383.
Queseda J.R., Gutterman J.U.. (1983): Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in an intermittent schedule in cancer patients. J. Natl. Cancer Inst., 70, 1041–1046.
Rosenblum M.G., Unger B.W., Gutterman J.U., Hersh E.M., David G.S., Fincke J.M. (1985): Modification of human leucocyte interferon pharmacology with monoclonal antibody. Cancer Res., 45, 2421–2424.
Capon D.J., Charnow S.M., Mordenti J., et al. (1989): Designing CD4 immunadhesins for AIDS therapy. Nature, 337, 525–531.
Sell S. (1987): Immunology, Immunopathology and Immunity, 4th edn. Amsterdam, Elsevier.
Berson S.A., Yalow R.S. (1966): State of human growth hormone in plasma and changes in stored solutions of pituitary growth hormone. J. Biol. Chem., 241, 5745–5749.
Baumann G., Stolar M.W., Amburn K., Barsario C.P., De Vries B.C. (1986): A specific growth hormone-binding protein in human plasma: initial characterization. J. Clin. Endocrinol. Metab., 62, 134–141.
Baumann G., Shaw M.A. (1990): A second lower affinity growth hormone binding protein in human plasma. J. Clin. Endocrinol. Metab., 70, 680–686.
Baumann G., Amburn K., Shaw M.A. (1988): The circulating growth hormone (GH)-binding protein complex: A major constituent of plasma GH in man. Endocrinology, 122, 976–984.
Baumann G., Shaw M.A., Amburn K. (1989): Regulation of plasma growth hormone-binding proteins in health and disease. Metabolism, 38, 683–689.
Baumann G., Amburn K., Buchanan T.A. (1987): The effect of circulating growth hormone-binding protein on metabolic clearance, distribution, and degradation of human growth hormone. J. Clin. Endocrinol. Metab., 64, 657–660.
Baumann G., Shaw M.A., Buchanan T.A. (1988): In vivo kinetics of a covalent growth hormone-binding protein complex. Metabolism, 38, 330–333.
Leung D.W., Spencer S.A., Cachianes G. (1987): Growth hormone receptor and serum binding protein: purification cloning and expression. Nature, 330, 537–543.
Amit T., Barkey R.J., Youdim M.B.H., Hochberg Z. (1990): A new and convenient assay for growth hormone-binding protein activity in human serum. J. Clin. Endocrinol. Metab., 71, 474–479.
Laron Z., Klinger B., Erster B., Silbergeld. (1989): Serum GH binding protein activities identifies the heterozygous carriers for Laron type dwarfism. Acta Endocrinol., 121, 603–608.
Baumann G., Shaw M.A., Merimee T.J. (1989): Low levels of high-affinity growth hormone-binding protein in African pygmies. N. Engl. J. Med., 320, 1705–1709.
Rutanen E.M., Pekonen F. (1990): Insulin-like growth factors and their binding proteins. Acta Endocrinol., 123, 7–13.
Zapf J., Hauri C., Waldvogel M., et al. (1989): Recombinant insulin-like growth factor-I induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc. Natl. Acad. Sci. USA, 86, 3813–3817.
Binoux M., Lalou C., Lassarre C., Segovia B.. (1994): Regulation of IGF bioavailability by IGFBP proteases. In: Baxter R.C., Gluckman P.D., Rosenfeld R.G. (Eds.): The Insulin-like Growth Factors and their Regulatory Proteins. Amsterdam, Elsevier, pp. 217–226.
Havredaki M., Barona F. (1985): Variations in interferon inactivators and/or inhibitors in human serum and their relationship to interferon therapy. Jpn. J. Med. Sci. Biol., 38, 107–111.
Fernandez-Botran R., Vitetta E.S. (1990): A soluble, high-affinity, interleukin-4-binding protein is present in the biological fluids of mice. Proc. Natl. Acad. Sci. USA, 87, 4202–4206.
Lelchuk R., Playfair J.H.L. (1985): Serum IL-2 inhibitor in mice. I. Increase during infection. Immunology, 56, 113–118.
Malik S., Lantz M. Slevin M., Olsson I.. (1991): Infusion of recombinant human tumour necrosis factor (rhTNF) causes an increase in circulating TNF-binding protein in man. Int. J. Exp. Pathol., 72, A6.
Kleinbloesem C.H., van Brummelen P., van de Linde J.A., Voogol P.J., Breimer D.D. (1984): Nifedipine: kinetics and dynamics in healthy subjects. Clin. Pharm. Ther., 35, 742–749.
Van Cauter E., Refetoff S. (1985): Multifactorial control of the 24-hour secretory profiles of pituitary hormones. J. Endocrinol. Invest., 8, 381–391.
Hulse J.A., Rosenthal S.M., Cuttler L., Kaplan S.L., Grumbach M.M. (1986): The effect of pulsatile administration, continuous infusion and diurnal variation on the growth hormone response to GH-releasing hormone in normal men. J. Clin. Endocrinol. Metab., 63, 872–878.
Clark R.G., Jansson J-O., Isaksson O., Robinson I.C.A.F. (1985): Intravenous growth hormone: growth responses to patterned infusions in hypophysectomized rats. J. Endocrinol., 104, 53–61.
Tuvemo T. (1989): What is the best mode of growth hormone administration? Acta Paediatr. Scand., 362 Suppl., 44–49.
Tam C.S., Heersche J.N.M., Murray T.M., Parsons J.A. (1982): Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology, 110, 506–512.
Klabunde R.E., Burke S.E., Henkin J. (1990): Enhanced lytic efficacy of multiple bolus injections of tissue plasminogen activator in dogs. Thromb. Res., 58, 511–517.
Vickery B.H. (1991): Biological actions of synthetic analogues of luteinizing hormone-releasing hormone. In: Garzone P.D., Colburn W.A., Mokotoff M. (Eds) Pharmacokinetics and Pharmacodynamics. Vol. 3. Peptides, Peptoids and Proteins. Cincinnati, Harvey Whitney Books, pp. 41–49.
Wills R.J., Dennis S., Spiegel H.E., Gibson D.M., Nadler P.I. (1984): Interferon kinetics and adverse reactions after intravenous, intramuscular and subcutaneous injection. Clin. Pharm. Ther., 35, 722–727.
Supersaxo A., Hein W., Gallati H., Steffen H. (1988): Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application. Pharm. Res., 5, 472–476.
Supersaxo A., Hein W.R., Steffen H. (1990): Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm. Res., 7, 167–169.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Toon, S. The relevance of pharmacokinetics in the development of biotechnology products. European Journal of Drug Metabolism and Pharmacokinetics 21, 93–103 (1996). https://doi.org/10.1007/BF03190257
Issue Date:
DOI: https://doi.org/10.1007/BF03190257